Publications by authors named "Olaf Eickmeier"

Claim this Profile
V
Validation of the CFAbd-Score.kid, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis.
Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, Anton Barucha, Lutz Nährlich, Olaf Eickmeier

J Cyst Fibros· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel CFAbd-Score.kid reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results.
Jochen G Mainz, Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, Anton Barucha, Olaf Eickmeier

J Cyst Fibros· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.
Pauline Sadrieh, Lutz Nährlich, Carsten Schwarz, Olaf Eickmeier, Patience Eschenhagen

Klin Padiatr· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Role of microRNA-146a in Experimental Inflammation in Human Pulmonary Epithelial and Immune Cells and Expression in Inflammatory Lung Diseases.
Lucia Gronau, Ruth P Duecker, Silvija-Pera Jerkic, Olaf Eickmeier, Jordis Trischler

Int J Mol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proinflammatory pattern in the lower airways of non-asthmatic obese adolescents.
Desiree Gutmann, Melanie Dressler, Olaf Eickmeier, Eva Herrmann, Marta Kirwil

Cytokine· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Jochen G Mainz, Anton Barucha, Pu Huang, Lilith Bechinger, Franziska Duckstein, Olaf Eickmeier

Front Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
Sivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, Florian Stehling, Folke Brinkmann, Olaf Eickmeier

Lancet Reg Health Eur· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming Growth Factor ß1 and Gap Junction Protein Alpha 4 Gene Heterogeneity in Relation to the Severity of Clinical Disease in Cystic Fibrosis.
Joern Pascal Laubach, Michael Ludwig, Tabea Horn, Olaf Eickmeier, Christina Smaczny

Front Biosci (Landmark Ed)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Jochen G Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier

Front Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease.
Aniello Meoli, Olaf Eickmeier, Giovanna Pisi, Valentina Fainardi, Stefan Zielen

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis.
Jobst F Roehmel, Friederike J Doerfler, Cordula Koerner-Rettberg, Folke Brinkmann, Anne Schlegtendal, Olaf Eickmeier

Chest· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Epidemiology of Mycobacterium abscessus Isolates Recovered from German Cystic Fibrosis Patients.
Nils Wetzstein, Margo Diricks, Thomas A Kohl, Thomas A Wichelhaus, Sönke Andres, Olaf Eickmeier

Microbiol Spectr· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge.
Agathe Lepissier, Charlotte Addy, Kate Hayes, Sabrina Noel, Stéphanie Bui, Olaf Eickmeier

J Cyst Fibros· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Jochen G Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier

Front Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mannose-Binding Lectin (MBL) and Gap Junction Protein Alpha 4 (GJA4) Gene Heterogeneity in Relation to Severity of Clinical Disease in Cystic Fibrosis.
Joern Pascal Laubach, Michael Ludwig, Tabea Horn, Olaf Eickmeier, Christina Smaczny

Front Biosci (Landmark Ed)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coil embolisation for massive haemoptysis in cystic fibrosis.
Martha Dohna, Diane Miriam Renz, Florian Stehling, Christian Dohna-Schwake, Sivagurunathan Sutharsan, Olaf Eickmeier

BMJ Open Respir Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients.
Stefan Zielen, Gianna Reichert, Helena Donath, Jordis Trischler, Johannes Schulze, Olaf Eickmeier

J Asthma Allergy· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a Variant on Clinical Disease Phenotype in Homozygous Patients With Cystic Fibrosis.
Tabea Horn, Michael Ludwig, Olaf Eickmeier, Anne H Neerinex, Anke H Maitland-van der Zee

Front Genet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of Aspergillus fumigatus sensitization in cystic fibrosis.
Olaf Eickmeier, Ulrich M Zissler, Julia Wittschorek, Frederike Unger, Sabina Schmitt-Grohé

Clin Exp Allergy· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006-2016.
Nils Wetzstein, Christian Hügel, Thomas A Wichelhaus, Michael Hogardt, Olaf Eickmeier

Infection· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.
Christian Vogelberg, Stanley J Szefler, Elianne J L E Vrijlandt, Attilio L Boner, Michael Engel, Olaf Eickmeier

Eur Respir J· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidative stress-driven pulmonary inflammation and fibrosis in a mouse model of human ataxia-telangiectasia.
Ruth Duecker, Patrick Baer, Olaf Eickmeier, Maja Strecker, Jennifer Kurz

Redox Biol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.
Carsten Schwarz, Dominik Hartl, Olaf Eickmeier, Andreas Hector, Christian Benden

Mycopathologia· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis.
Olaf Eickmeier, Daniela Fussbroich, Klaus Mueller, Friederike Serve, Christina Smaczny

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Airway inflammation in mild cystic fibrosis.
Jonas Eckrich, Ulrich M Zissler, Friederike Serve, Patricia Leutz, Christina Smaczny, Olaf Eickmeier

J Cyst Fibros· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis